Wednesday, March 11, 2020 3:28:04 PM
That's right folks, unlike a "drug", "IMMCELZ™ product specifically reprograms cells of the immune system in order to specifically stop attack against the body's own tissues, while preserving immune responses against cancer and infectious diseases."
Press Release Line
Quote:
Creative Medical Technology Holdings Announces IMMCELZ™ Adoptive Immunotherapy Product
Clinical Stage Adult Stem Cell Therapy Company Discovers New Way to Stop Immune Diseases without Immune Suppression
NEWS PROVIDED BY
Creative Medical Technology Holdings, Inc.
Mar 11, 2020, 08:15 ET
PHOENIX, March 11, 2020 /PRNewswire/ -- Creative Medical Technology Holdings announced today, what appears to be, the first personalized adoptive immunotherapy for treatment of autoimmunity, which the Company named "IMMCELZ™".
Utilizing the newly discovered properties of regenerative cells to alter immune cells, the Company has found a new method of developing "patient-specific" treatments for diseases in which the immune system pathologically starts to attack healthy tissues in the body, a state termed "autoimmunity".
The autoimmune disease market is estimated to be approximately $38 billion annually1. Common autoimmune diseases include Type 1 diabetes, Rheumatoid arthritis, Psoriasis/Psoriatic arthritis, Multiple sclerosis, Systemic lupus erythematous (lupus), Inflammatory bowel diseases, Myasthenia gravis, Vasculitis, Celiac disease and Hashimoto's Thyroiditis.
"Current drugs treating autoimmunity act to suppress the immune system globally, thus increasing the risks of infections and cancers," said Dr. Thomas Ichim, Chief Scientific Officer of the Company and Co-Inventor of the technology. "In contrast, the IMMCELZ™ product specifically reprograms cells of the immune system in order to specifically stop attack against the body's own tissues, while preserving immune responses against cancer and infectious diseases."
IMMCELZ™, which is protected by trade secrets and published US patent application 15/987739, utilizes adult stem cells derived from qualified donors, to endow specific properties to patient immune cells. After the patient immune cells are incubated with the donor stem cells, the immune cells are extracted and re-injected back into the patient. These "reprogrammed cells" subsequent "educate" other cells of the immune system to stop attacking the body, while preserving ability to attack cancers and foreign pathogens.
"While the results are preliminary, and additional research is needed before clinical trials may begin, we believe that the current interest in cellular immunotherapy, will turn in using these types of approaches for treatment of autoimmunity," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "Examples of cellular immunotherapies for cancer include CAR-T cells developed by Kite Pharma, which was acquired by Gilead for $11.9 Billion2. Our corporate philosophy is that cells are intrinsically superior therapeutics to chemical drugs, and we believe our entry into the field of autoimmunity will delivery a higher level of therapeutic effect in autoimmunity as compared to conventional approaches."
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.
Forward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at https://www.sec.gov.
Timothy Warbington, CEO
www.Creativemedicaltechnology.com
https://caverstem.com
https://femcelz.com
http://www.stemspine.com
1 https://www.marketwatch.com/press-release/autoimmune-disease-market-industry-outlook-size-forecast-2018-2025-2019-10-22
2 https://uk.reuters.com/article/uk-kite-pharma-m-a-gilead-sciences/gilead-to-buy-kite-for-promising-cancer-therapies-in-12-billion-deal-idUKKCN1B810W
SOURCE Creative Medical Technology Holdings, Inc.
Related Links
https://creativemedicaltechnology.com
Recent CELZ News
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/03/2023 08:05:12 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 09:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 01:00:18 PM
- Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements • PR Newswire (US) • 06/28/2023 12:00:00 PM
- Creative Medical Technology Announces $2 Million Share Repurchase Program • PR Newswire (US) • 06/12/2023 12:01:00 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 06/12/2023 12:00:00 PM
- Creative Medical Technology Holdings Announces Reverse Stock Split • PR Newswire (US) • 06/09/2023 04:30:00 PM
- Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform • PR Newswire (US) • 05/31/2023 12:00:00 PM
- Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development • PR Newswire (US) • 05/22/2023 12:30:00 PM
- Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line • PR Newswire (US) • 05/18/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM